An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Figure 1. From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.
CitationFull text
Figure 2. Physicochemical characterization of purified Affitoxin. From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.
Figure 7. Affitoxin efficacy in the presence of Affibody excess. From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.
Figure 6. Effect of exposure time on Affitoxin efficacy. From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.
Figure 3. Kinetic analysis of ZHER2:342 Affibody molecule (A) or Affitoxin (B) binding to HER2/Fc-covered surface. From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.
Figure 4. Specificity of Affitoxin binding confirmed by confocal imaging and flow cytometry. From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.
Figure 5. Efficacy of Affitoxin measured by inhibition of protein synthesis (A) and intracellular ATP level (B). From: Affitoxin – A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-Positive Tumors.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on